Gallup puts US adult GLP-1 use at 11%. PepsiCo and Hershey shares are down over the past year, though Hershey's breath mint sales are growing.
Recap by typeshit. Full story at The Motley Fool.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
An indirect comparison shown at EASD 2026 put orforglipron ahead of Rybelsus at 52 weeks. GlobalData's analyst says head-to-head trials are still needed.
He lists what Japanese clinics advertise BPC-157, TB-500 and Epitalon for, and notes the FDA has flagged missing human safety data for several of them.
Loading…